PROCEPT BioRobotics Corporation (PRCT) — Stock Score Summary

PROCEPT BioRobotics Corporation (PRCT) has a MoatMap StockRank of 24/100 based on Quality (44/100), Value (39/100), and Momentum (27/100) factor scores. The current signal is SELL. Procept BioRobotics is a high-growth surgical robotics company with strong clinical adoption, but it remains unprofitable with a high valuation multiple, lacking a clear margin of safety or direct macro tailwind.

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company focused on developing transformative solutions in urology, primarily for the treatment of benign prostatic hyperplasia (BPH). The company's competitive moat is anchored by its proprietary AquaBeam Robotic System, which delivers Aquablation therapy—the first FDA-cleared, image-guided, heat-free waterjet tissue ablation technology. Backed by robust clinical data demonstrating superior safety and efficacy profiles compared to traditional surgeries, PROCEPT is rapidly establishing Aquablation as the new standard of care for BPH.

Key Financial Metrics

Price$28.78
Market Cap$1.5B
P/E (Forward)-31.18
Price/Book4.42
Return on Equity-27.8%
Return on Invested Capital-20.8%
Debt/Equity22.43
Gross Margin64.0%
Operating Margin-39.2%
Revenue Growth20.2%
Free Cash Flow$-43M

PROCEPT BioRobotics Corporation operates in the Medical Devices industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is PROCEPT BioRobotics Corporation’s (PRCT) StockRank?
MoatMap’s StockRank for PROCEPT BioRobotics Corporation (PRCT) is 24/100, with a Sell signal. It is a composite of Quality (44), Value (39), and Momentum (27) factor ranks across MoatMap’s 19,000+ stock universe.
Does PROCEPT BioRobotics Corporation have an economic moat?
PROCEPT BioRobotics Corporation (PRCT) has a Quality factor score of 44/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is PROCEPT BioRobotics Corporation a buy, hold, or sell?
MoatMap’s current signal for PROCEPT BioRobotics Corporation (PRCT) is Sell, based on a StockRank of 24/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is PROCEPT BioRobotics Corporation in?
PROCEPT BioRobotics Corporation (PRCT) operates in the Healthcare sector, specifically the Medical Devices industry (United States).
Browse all ranked stocksPRCT deep dive reportAI ChampionsHow we score stocksSense-check another stock